← Leaderboards
Patrick Loi
Harvard Medical School
$84,628
Attributed
$84,628
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $39.6K · FY2021–23$50K$37.5K$25K$12.5K$0
'21
'22
'23
Funding mix
By agency
NIH$84,628 · 1
By mechanism
F31$84,628 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Nils Gehlenborg$19,033,231
- Anna I Weaver$221,404
- Sophie Helaine$3,006,670
- Sofia Hu$155,482
- Chad Brandon Stein$51,948
Others in their field
Other Emerging Leaders on “Advanced Disease”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Chanza Baytop · Westat, Inc.$271,217,917
- Kimberly Smith · Ppd Development Lp$116,656,661
- Klaus Romero · Critical Path Institute$88,602,036
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$59,913,818
Research focus
Advanced DiseaseComplexAutomobile DrivingAdvanced Malignant NeoplasmCombined Modality TherapyBiological MarkersBraf GeneCancer CellCancer Cell LineCancer EtiologyCell DeathAntitumor AgentCell LineCellsCessation Of LifeChip-SeqChromatinClinicClinical TrialsClosure By ClampColon Cancer Cell LineColorectal CancerColorectal Cancer TreatmentCrispr/Cas Technology
Grant awards (3)
Investigating the role of EZH2 as a therapeutic target in colorectal cancers$10,562
F31 · FY2023 · CA · contact PI
Investigating the role of EZH2 as a therapeutic target in colorectal cancers$34,515
F31 · FY2022 · CA · contact PI
Investigating the role of EZH2 as a therapeutic target in colorectal cancers$39,551
F31 · FY2021 · CA · contact PI